Clinical Trial Search

Primary: Number of Participants With Emergence of Suicidal Ideation During Period II/III — 2 participants

Primary: Difference in Endogenous (Hepatic) Glucose Output During a High-dose Insulin Infusion From Baseline to After 12 Weeks of Treatment. — -0.06; -0.011; -0.01 mg/kg/min…

Primary: The Percentage of Heartburn-free Days (24-hour Periods) During the 6-month Maintenance Treatment Phase (ITT Population). — 82.58; 62.17 Percentage of Days — p=<0.0001

Primary: Treatment-emergent Adverse Events Experienced by >=5% of Patients in Any Treatment Group — 3; 2; 3; 2 Participants

Primary: The Cumulative Number of Newly Gadolinium-enhancing T1-weighted Lesions on Cranial Magnetic Resonance Imaging (MRI)s Through Week 23. — 1.20; 1.00; 2.00; 2.40 Lesions…

Primary: Best Overall Response — 0; 2; 25; 42 participants

Primary: Number of Participants With the Indicated Response — 6; 11; 20; 7 participants

Primary: Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Total Score at 6 Weeks — -17.8; -13.8 Units on a Scale — p=<0.0001

Primary: Number of Patients With Prothrombin Time Results Within the Therapeutic Range After 2 Weeks — 48; 45 participants

Primary: Percentage of Participants With Serum Bactericidal Activity of ≥ 1:8 for the Menactra® Meningococcal Serogroups Pre-vaccination, and at 7 Days or 14 Days Post-booster or…

Primary: Best Overall Response — 0; 0; 20; 16 participants

Primary: Patients' Overall Response — 0; 15; 2; 4 Participants

Primary: Mean Change From Baseline in Daily rTNSS Over the Entire Treatment Period (28 Days) — -2.10; -2.17 points on a scale — p=0.845

Primary: Percentage of Patients Alive at 1 Year (1-Year Survival Rate) — 39; 31 percentage of participants

Primary: Number of Participants With a Diagnosis of Rheumatoid Arthritis (RA) by American Rheumatism Association (ARA) Criteria and/or Discontinued Due to Lack of Efficacy — 12…